Keywords
PSA
kinetyka PSA
zmiana PSA po radioterapii
nadir PSA
Stereotactic Body Radiotherapy
SBRT
CyberKnife
How to Cite
Abstract
Prostate-specific antygen (PSA) pozostaje najlepszym biomarkerem do monitorowania pacjentów z rakiem prostaty po zakończeniu radykalnego leczenia. Kinetyka jego spadku oraz osiągane nadiry podlegały licznym badaniom w klasycznej radioterapii oraz brachyterapii, sugerując ich znaczenie jako ważnych czynników prognostycznych. W dobie rozwoju radioterapii stereotaktycznej, wysoce hipofrakcjonowanej, istotne jest zrozumienie zachowania PSA po tej formie leczenia. Praca prezentuje aktualne dane literaturowe w tym zakresie wykazujące charakterystyczną kinetykę spadku PSA (gwałtowny spadek w 1 roku oraz dalszy, wolniejszy w latach kolejnych) oraz wysokie odsetki nadirów PSA <0.5 ng/ml (ponad 70%). Prace ukazują także dość częste (ok 30-40%) występowanie zjawiska PSA bounce analogicznie do brachyterapii.
References
Krajowy Rejestr Nowotworów, Dane epidemiologiczne za rok 2013, www.onkologia.org.pl, dostęp: sierpień 2017
World Cancer Report 2014. International Agency for Research on Cancer, World Health Organization. 2014. ISBN 978-92-832-0432-9
Kaplan ID, Cox RS, Bagshaw MA, A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy, Cancer 68 (1991) 400–405.
Katz A, Kang J, Stereotactic Body Radiation Therapy for Low-, Intermediate-, and High-Risk Prostate Cancer: Disease Control and Quality of Life at 6 Years, Int J Radiat Oncol Biol Phys 2013;87:S24-5
Lee WR, Hanlon AL, Hanks GE, Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival, J. Urol. 156 (1996) 450–453.
Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II, Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial, Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 677–685.
Shipley WU, Thames HD, Sandler HM, et al., Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis, JAMA 281 (1999) 1598–1604.
Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, et al., Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate, Radiother. Oncol. 40 (1996) 159–162.
Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, et al., Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate, Radiother. Oncol. 40 (1996) 159–162.
Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al., PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis, Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 1140–1150.
Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics
and minima after prostate cancer radiotherapy are predictive of overall survival. int J Radiat oncol Biol Phys 2006;66: 20–4.
Chauvet B, Félix-Faure C, Lupsascka N, et al., Prostate-specific antigen de- cline: a major prognostic factor for prostate cancer treated with radiation therapy, J. Clin. Oncol. 12 (1994) 1402–1407.
Ritter M, Messing E, Shanahan T, Potts S, Chappell R, Kinsella T, Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer, J. Clin. Oncol. 10 (1992) 1208–1217. [14] Zagars GK, Pollack A, The fall and rise of prostate-specific antigen: kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer, Cancer 72 (1993) 832–842.
Zagars GK, Pollack A, Kinetics of serum prostate-specific antigen after ex- ternal beam radiation for clinically localized prostate cancer, Radiother. Oncol. 44 (1997) 213–221.
. Patel N, Souhami L, Mansure JJ, et al. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypo- fractionated external beam radiotherapy. Brachytherapy 2014;13: 450-455.
. Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006;64:512-517.
. Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: De- scriptions and implications. Int J Radiat Oncol Biol Phys 2003;56: 448-453.
Hauck CR, Ye H, Chen PY, Gustafson GS, Limbacher A, Krauss DJ, Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer, Int J Radiation Oncol Biol Phys, Vol. 98, No. 1, pp. 108e114, 2017
Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A, Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir, Radiation Oncology 2014, 9:42
Phak JH, Kim HJ, Kim WC, Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy for low- and intermediate-risk prostate cancer, Cancer Treatment Communications 5 (2016) 46–50
Park YH, Choi IY, Yoon SC, Jang HS, Moon HW, Hong SH, et al, Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer, Prostate International 3 (2015) 6e9
Kole TP, Chen LN, Obayomi-Davies O, Kim JS, Lei S, Suy S, Dritschilo A, Collins SP, Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer, Acta Oncologica,2015, 54:6, 832-838,
Kataria S, Koneru H, Guleria S, Danner M, Ayoob M, Yung T, et al, Prostate- Speci c Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure? Front. Oncol. 2017, 7:157.
Konkol M, Galuba A, Milecki P, Skrobala A, Jodda A, Adamczyk M, Litoborska J, PSA kinetics in prostate cancer patients after SBRT radiotherapy using CyberKnife, Radiotherapy and Oncology, 2016-04-01, Volume 119, Pages S646-S646
Straka CA, Kim D, Cho L, Yan J, Lotan Y, Kavanagh B, et al, Early and Multiple PSA Bounces Can Occur Following High-Dose Prostate Stereotactic Body Radiation Therapy: Subset Analysis of a Phase 1/2 Trial, Int J Radiation Oncol Biol Phys Volume 90 Number 1S, Supplement 2014
Zelefsky MJ, PSA bounce versus biochemical failure following prostate brachytherapy. Nat Clin Pract Urol (2006) 3(11):578–9.
Lo AC, Morris WJ, Lapointe V, Hamm J, Keyes M, Pickles T, et al. Prostate- specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival. Int J Radiat Oncol Biol Phys (2014) 88(1):87–93.